Synthetic C-reactive protein (CRP) rescues mice from lethal endotoxin shock or bacterial infection by suppressing tumor necrosis factor (TNF-α), but in turn, enhances Kupffer cell phagocytic activity. We herein assessed the influence of CRP in human peripheral blood mononuclear cells (PBMCs). When human PBMCs were stimulated in vitro with penicillin-treated Streptococcus pyogenes, bacterial DNA motifs and lipopolysaccharide with or without synthetic CRP, CRP suppressed the production of TNF-α and IL-12, but not that of IFN-γ. This was also the case for the in vitro Shwartzman reaction induced in PBMCs. CRP also decreased high-mobility group box 1 production from macrophages, which is crucial in the later phase of endotoxin/septic shock. However, CRP upregulated the perforin expression by CD56(+) NK cells and increased their antitumor cytotoxicity. CRP may thus be a potent immunomodulatory factor in the human immune system, suggesting its therapeutic potential for use against human septic shock.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708291 | PMC |
| http://dx.doi.org/10.1007/s10753-013-9604-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.
Rheumatol Ther
January 2025
OPAL Rheumatology Ltd, Sydney, NSW, Australia.
Introduction: This study sought to describe treatment patterns, persistence, and effectiveness of upadacitinib (UPA) alone and compared to other Janus kinase inhibitors (JAKis) or tumor necrosis factor inhibitors (TNFis) in patients with rheumatoid arthritis (RA).
Methods: This retrospective, non-interventional study used the OPAL dataset, derived from electronic medical records. Patients initiated UPA (N = 2624), other JAKis (baricitinib and tofacitinib [N = 925]), or TNFis (adalimumab, etanercept, certolizumab, golimumab, infliximab [N = 3540]) between May 2020 and March 2023.
Preconception Chlamydia trachomatis seropositivity and fecundability, live birth, and adverse pregnancy outcomes.
Fertil Steril
December 2024
Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas; Academic Research, Advocate Aurora Research Institute, Milwaukee, Wisconsin. Electronic address:
Objective: To study the impact of preconception Chlamydia trachomatis seropositivity on fecundability, live birth, and pregnancy loss and to assess the effect of low-dose aspirin therapy (81 mg/day) on live birth and pregnancy loss.
Design: Preconception cohort study conducted using data and specimens from the Effects of Aspirin in Gestation and Reproduction study-a randomized placebo-controlled trial.
Patients: A total of 1,228 individuals with proven fecundity and a history of 1-2 pregnancy losses.
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.
RMD Open
December 2024
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Objectives: To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase 3b COSMOS trial. Subgroups were defined by baseline demographics, disease characteristics and prior/ongoing therapies.
Methods: Patients with active PsA (tender joint count (TJC) and swollen joint count (SJC) both ≥3) and TNFi-IR were randomised 2:1 to receive guselkumab 100 mg at week 0, week 4, then every 8 weeks through week 44 or to placebo with cross-over to guselkumab 100 mg at week 16 (early escape) or week 24 (planned).
Axial Spondyloarthritis: A Review.
JAMA
December 2024
Division of Arthritis and Rheumatic Diseases (OP09), Oregon Health & Science University, Portland.
Article Synopsis
- * The main symptom is inflammatory back pain starting before age 45, often accompanied by morning stiffness and improved by exercise; it can also involve issues in peripheral joints and other inflammatory conditions.
- * Diagnosis is often delayed by 6 to 8 years and relies on a combination of patient history, lab tests, and imaging; treatment usually starts with physical therapy and NSAIDs, but many patients may need advanced biologic therapies to manage their symptoms effectively.
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
Ann Rheum Dis
November 2024
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
Article Synopsis
- - The study aimed to evaluate the effectiveness and safety of ivarmacitinib, a JAK 1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) who did not respond adequately to standard treatments.
- - Participants were divided into three groups to receive either placebo, ivarmacitinib 4 mg, or 8 mg once daily, with primary outcomes measured after 24 weeks based on 20% improvement in RA symptoms (ACR20).
- - Results showed significantly higher improvement rates in those taking ivarmacitinib compared to placebo, with manageable safety concerns, indicating it could be a promising option for this patient population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!